A slowly growing malignant neoplasm derived from cartilage cells, occurring most frequently in pelvic bones or near the ends of long bones, in middle-aged and old people. Most chondrosarcomas arise de novo, but some may develop in a preexisting benign cartilaginous lesion or in patients with ENCHONDROMATOSIS. (Stedman, 25th ed)
A rare aggressive variant of chondrosarcoma, characterized by a biphasic histologic pattern of small compact cells intermixed with islands of cartilaginous matrix. Mesenchymal chondrosarcomas have a predilection for flat bones; long tubular bones are rarely affected. They tend to occur in the younger age group and are highly metastatic. (DeVita Jr et al., Cancer: Principles & Practice of Oncology, 3d ed, p1456)
A benign neoplasm derived from mesodermal cells that form cartilage. It may remain within the substance of a cartilage or bone (true chondroma or enchondroma) or may develop on the surface of a cartilage (ecchondroma or ecchondrosis). (Dorland, 27th ed; Stedman, 25th ed)
Tumors or cancer located in bone tissue or specific BONES.
Benign growths of cartilage in the metaphyses of several bones.
A malignant tumor arising from the embryonic remains of the notochord. It is also called chordocarcinoma, chordoepithelioma, and notochordoma. (Dorland, 27th ed)
A sarcoma, usually a liposarcoma or malignant fibrous histiocytoma, with an abundant component of myxoid tissue resembling primitive mesenchyme containing connective tissue mucin. (Stedman, 25th ed)
A non-vascular form of connective tissue composed of CHONDROCYTES embedded in a matrix that includes CHONDROITIN SULFATE and various types of FIBRILLAR COLLAGEN. There are three major types: HYALINE CARTILAGE; FIBROCARTILAGE; and ELASTIC CARTILAGE.
Neoplasms of the base of the skull specifically, differentiated from neoplasms of unspecified sites or bones of the skull (SKULL NEOPLASMS).
Hereditary disorder transmitted by an autosomal dominant gene and characterized by multiple exostoses (multiple osteochondromas) near the ends of long bones. The genetic abnormality results in a defect in the osteoclastic activity at the metaphyseal ends of the bone during the remodeling process in childhood or early adolescence. The metaphyses develop benign, bony outgrowths often capped by cartilage. A small number undergo neoplastic transformation.
Neoplasms developing from some structure of the connective and subcutaneous tissue. The concept does not refer to neoplasms located in connective or soft tissue.
A sarcoma originating in bone-forming cells, affecting the ends of long bones. It is the most common and most malignant of sarcomas of the bones, and occurs chiefly among 10- to 25-year-old youths. (From Stedman, 25th ed)
A set of twelve curved bones which connect to the vertebral column posteriorly, and terminate anteriorly as costal cartilage. Together, they form a protective cage around the internal thoracic organs.
Bones that constitute each half of the pelvic girdle in VERTEBRATES, formed by fusion of the ILIUM; ISCHIUM; and PUBIC BONE.
Enzymes which catalyze the elimination of glucuronate residues from chondroitin A,B, and C or which catalyze the hydrolysis of sulfate groups of the 2-acetamido-2-deoxy-D-galactose 6-sulfate units of chondroitin sulfate. EC 4.2.2.-.
Rare, benign, chronic, progressive metaplasia in which cartilage is formed in the synovial membranes of joints, tendon sheaths, or bursae. Some of the metaplastic foci can become detached producing loose bodies. When the loose bodies undergo secondary calcification, the condition is called synovial osteochondromatosis.
Glycoproteins which have a very high polysaccharide content.
A cartilage-capped benign tumor that often appears as a stalk on the surface of bone. It is probably a developmental malformation rather than a true neoplasm and is usually found in the metaphysis of the distal femur, proximal tibia, or proximal humerus. Osteochondroma is the most common of benign bone tumors.
Cancer or tumors of the MAXILLA or upper jaw.
Fibrous, bony, cartilaginous and osteocartilaginous fragments in a synovial joint. Major causes are osteochondritis dissecans, synovial chondromatosis, osteophytes, fractured articular surfaces and damaged menisci.
Multiple formation of chondromas. (Dorland, 27th ed)
Individual's rights to obtain and use information collected or generated by others.
The compartment containing the anterior extremities and half the inferior surface of the temporal lobes (TEMPORAL LOBE) of the cerebral hemispheres. Lying posterior and inferior to the anterior cranial fossa (CRANIAL FOSSA, ANTERIOR), it is formed by part of the TEMPORAL BONE and SPHENOID BONE. It is separated from the posterior cranial fossa (CRANIAL FOSSA, POSTERIOR) by crests formed by the superior borders of the petrous parts of the temporal bones.
Works containing information articles on subjects in every field of knowledge, usually arranged in alphabetical order, or a similar work limited to a special field or subject. (From The ALA Glossary of Library and Information Science, 1983)
Lists of words, usually in alphabetical order, giving information about form, pronunciation, etymology, grammar, and meaning.
The inferior region of the skull consisting of an internal (cerebral), and an external (basilar) surface.
The SKELETON of the HEAD including the FACIAL BONES and the bones enclosing the BRAIN.
Intraoperative computer-assisted 3D navigation and guidance system generally used in neurosurgery for tracking surgical tools and localize them with respect to the patient's 3D anatomy. The pre-operative diagnostic scan is used as a reference and is transferred onto the operative field during surgery.
Cancers or tumors of the LARYNX or any of its parts: the GLOTTIS; EPIGLOTTIS; LARYNGEAL CARTILAGES; LARYNGEAL MUSCLES; and VOCAL CORDS.
A tubular organ of VOICE production. It is located in the anterior neck, superior to the TRACHEA and inferior to the tongue and HYOID BONE.
Tissue that supports and binds other tissues. It consists of CONNECTIVE TISSUE CELLS embedded in a large amount of EXTRACELLULAR MATRIX.

Analysis of acute vascular damage after photodynamic therapy using benzoporphyrin derivative (BPD). (1/542)

Benzoporphyrin derivative monoacid ring A (BPD-MA, verteporfin) is currently under investigation as a photosensitizer for photodynamic therapy (PDT). Since BPD exhibits rapid pharmacokinetics in plasma and tissues, we assessed damage to tumour and muscle microvasculature when light treatment for PDT was given at short times after injection of photosensitizer. Groups of rats with chondrosarcoma were given 2 mg kg(-1) of BPD intravenously 5 min to 180 min before light treatment of 150 J cm(-2) 690 nm. Vascular response was monitored using intravital microscopy and tumour cure was monitored by following regrowth over 42 days. For treatment at 5 or 30 min after BPD injection, blood flow stasis was limited to tumour microvasculature with lesser response in the surrounding normal microvasculature, indicating selective targeting for damage. No acute changes were observed in vessels when light was given 180 min after BPD injection. Tumour regression after light treatment occurred in all animals given PDT with BPD. Long-term tumour regression was greater in animals treated 5 min after BPD injection and least in animals given treatment 180 min after drug injection. The correlation between the timing for vascular damage and cure implies that blood flow stasis plays a significant role in PDT-induced tumour destruction.  (+info)

The EWS/TEC fusion protein encoded by the t(9;22) chromosomal translocation in human chondrosarcomas is a highly potent transcriptional activator. (2/542)

The EWS/TEC gene fusion generated by the t(9;22) chromosomal translocation found in extraskeletal myxoid chondrosarcomas encodes a fusion protein containing the amino-terminal domain of the EWS protein fused to the whole coding sequence of the orphan nuclear receptor TEC. We have compared the DNA-binding and transcriptional activation properties of various TEC isoforms and the corresponding EWS/TEC fusion proteins. Band-shift experiments show that the full-length TEC receptor can efficiently bind the NGFI-B Response Element (NBRE), whereas an isoform lacking the entire carboxyl-terminal domain of the receptor binds much less efficiently the NBRE. Addition of the amino-terminal domain of EWS to either isoforms does not alter significantly their DNA-binding properties to the NBRE. Co-transfection experiments of COS cells and human chondrocytes indicate that whereas TEC moderately activates transcription from a NBRE-containing promoter, the corresponding EWS/TEC fusion protein is a highly potent transcriptional activator of the same promoter, being approximately 270-fold more active than the native receptor. EWS/TEC may thus exert its oncogenic potential in chrondrosarcomas by activating the transcription of target genes involved in cell proliferation.  (+info)

Sulphation heterogeneity in the trisaccharide (GalNAcSbeta1, 4GlcAbeta1,3GalNAcS) isolated from the non-reducing terminal of human aggrecan chondroitin sulphate. (3/542)

We report here the isolation and sulphation isomer analyses of trisaccharides GalNAcS(beta1,4)GlcA(beta1,3)GalNAcS (in which S indicates sulphate) derived from the non-reducing termini of aggrecan chondroitin sulphate. Rat chondrosarcoma and human aggrecans were digested for 1 h at 37 degrees C with 30 micro-units of endo-chondroitinase ABC per microgram of chondroitin sulphate, and trisaccharides were isolated from the digests by ToyoPearl HW40S gel-filtration chromatography. Four trisaccharide species were identified; their sulphation isomer compositions, as determined by digestion with chondroitinase ACII and fluorescence-based ion-exchange HPLC, were GalNAc4Sbeta1,4GlcAbeta1,3GalNAc4S, GalNAc4Sbeta1,4GlcAbeta1,3GalNAc6S, GalNAc4,6Sbeta1,4GlcAbeta1, 3GalNAc4S and GalNAc4,6Sbeta1,4GlcAbeta1,3GalNAc6S. The abundances of such sequences in chondroitin sulphate on aggrecan from normal (foetal to 72 years of age) and from osteoarthritic human knee cartilages were also established. The results showed that non-reducing terminal GalNAc4S or GalNAc4,6S can be linked to either a 4-sulphated or a 6-sulphated disaccharide, suggesting that the sulphation of the last disaccharide might not have a direct effect on the specificity of chondroitin sulphate terminal GalNAc sulphotransferases. Furthermore, for each aggrecan preparation examined, the 4S-to-6S ratio of all chain interior disaccharides was equivalent to that in the last repeating disaccharides at the non-reducing terminus, suggesting that neither chondroitin 4-sulphotransferase nor chondroitin 6-sulphotransferase shows preferential activity near the chain terminus.  (+info)

EXT-mutation analysis and loss of heterozygosity in sporadic and hereditary osteochondromas and secondary chondrosarcomas. (4/542)

Osteochondromas occur as sporadic solitary lesions or as multiple lesions, characterizing the hereditary multiple exostoses syndrome (EXT). Approximately 15% of all chondrosarcomas arise within the cartilaginous cap of an osteochondroma. EXT is genetically heterogeneous, and two genes, EXT1 and EXT2, located on 8q24 and 11p11-p12, respectively, have been cloned. It is still unclear whether osteochondroma is a developmental disorder or a true neoplasm. Furthermore, it is unclear whether inactivation of both alleles of an EXT gene, according to the tumor-suppressor model, is required for osteochondroma development, or whether a single EXT germline mutation acts in a dominant negative way. We therefore studied loss of heterozygosity and DNA ploidy in eight sporadic and six hereditary osteochondromas. EXT1- and EXT2-mutation analysis was performed in a total of 34 sporadic and hereditary osteochondromas and secondary peripheral chondrosarcomas. We demonstrated osteochondroma to be a true neoplasm, since aneuploidy was found in 4 of 10 osteochondromas. Furthermore, LOH was almost exclusively found at the EXT1 locus in 5 of 14 osteochondromas. Four novel constitutional cDNA alterations were detected in exon 1 of EXT1. Two patients with multiple osteochondromas demonstrated a germline mutation combined with loss of the remaining wild-type allele in three osteochondromas, indicating that, in cartilaginous cells of the growth plate, inactivation of both copies of the EXT1 gene is required for osteochondroma formation in hereditary cases. In contrast, no somatic EXT1 cDNA alterations were found in sporadic osteochondromas. No mutations were found in the EXT2 gene.  (+info)

Chemical modification and site-directed mutagenesis of conserved HXXH and PP-loop motif arginines and histidines in the murine bifunctional ATP sulfurylase/adenosine 5'-phosphosulfate kinase. (5/542)

The sulfurylase domain of the mouse bifunctional enzyme ATP sulfurylase/adenosine 5'-phosphosulfate (APS) kinase contains HXXH and PP-loop motifs. To elucidate the functional importance of these motifs and of conserved arginines and histidines, chemical modification and site-directed mutagenesis studies were performed. Chemical modification of arginines and histidines with phenylglyoxal and diethyl pyrocarbonate, respectively, renders the enzyme inactive in sulfurylase, kinase, and overall assays. Data base searches and sequence comparison of bifunctional ATP sulfurylase/APS kinase and monofunctional ATP sulfurylases shows a limited number of highly conserved arginines and histidines within the sulfurylase domain. Of these conserved residues, His-425, His-428, and Arg-421 are present within or near the HXXH motif whereas His-506, Arg-510, and Arg-522 residues are present in and around the PP-loop. The functional role of these conserved residues was further studied by site-directed mutagenesis. In the HXXH motif, none of the alanine mutants (H425A, H428A, and R421A) had sulfurylase or overall activity, whereas they all exhibited normal kinase activity. A slight improvement in reverse sulfurylase activity (<10% residual activity) and complete restoration of forward sulfurylase was observed with R421K. Mutants designed to probe the PP-loop requirements included H506A, R510A, R522A, R522K, and D523A. Of these, R510A exhibited normal sulfurylase and kinase activity, R522A and R522K showed no sulfurylase activity, and H506A had normal sulfurylase activity but produced an effect on kinase activity (<10% residual activity). The single aspartate, D523A, which is part of the highly conserved GRD sequence of the PP-loop, affected both sulfurylase and kinase activity. This mutational analysis indicates that the HXXH motif plays a role only in the sulfurylase activity, whereas the PP-loop is involved in both sulfurylase and kinase activities. Residues specific for sulfurylase activity have also been distinguished from those involved in kinase activity.  (+info)

Up-regulation of MDC15 (metargidin) messenger RNA in human osteoarthritic cartilage. (6/542)

OBJECTIVE: The aim of the study was to investigate the messenger RNA (mRNA) expression of the disintegrin metalloproteinase MDC15 (metargidin, or ADAM-15) in normal and osteoarthritic (OA) articular cartilage. METHODS: In situ hybridization experiments and reverse transcription-polymerase chain reaction (RT-PCR) were performed on tissue samples of adult normal and OA articular cartilage. RESULTS: MDC15 mRNA could be detected in normal articular cartilage by RT-PCR using tissue-extracted total RNA as a template. However, the mRNA level remained below the sensitivity of in situ hybridization. In contrast, in situ hybridizations of OA cartilage revealed an intense staining with the MDC15-specific riboprobes. The extension of the analysis to chondrosarcomas showed a strong up-regulation of MDC15 mRNA in these malignant transformed cells. CONCLUSION: Our results demonstrate a markedly strong up-regulation of MDC15 in adult OA and neoplastic cartilage compared with adult normal articular cartilage, indicating a potential role of the disintegrin metalloproteinase in cartilage remodeling.  (+info)

Reconstruction and limb salvage after resection for malignant bone tumour of the proximal humerus. A sling procedure using a free vascularised fibular graft. (7/542)

We assessed the intermediate functional results of eight patients after wide resection of the proximal humerus for malignant bone tumour. We used a free vascularised fibular graft as a functional spacer and a sling procedure to preserve passive scapulohumeral movement. Scapulohumeral arthrodesis was not carried out. Five patients had osteosarcoma, two achondrosarcoma and one a malignant fibrous histiocytoma of the bone. The mean duration of follow-up was 70 months (median, 76) for the seven patients who were still alive at the time of the latest follow-up. One patient died from the disease 12 months after surgery. There were no local recurrences. The functional results were described and graded quantitatively according to the rating system of the Musculoskeletal Tumour Society. Our results were satisfactory with regard to pain, emotional acceptance and manual dexterity. Function and lifting ability were unsatisfactory in two patients. One patient had delayed union between host and graft, but this united after six months without further surgery. Radiographs of the shoulder showed absorption or collapse of the head of the fibula in four of the eight patients and a fracture in another. No functional problems related to absorption or fracture of the head of the fibula were noted. There was no infection or subluxation of the head. We conclude that this is a reasonably effective technique of limb salvage after resection of the proximal humerus.  (+info)

Fusion of the EWS-related gene TAF2N to TEC in extraskeletal myxoid chondrosarcoma. (8/542)

Extraskeletal myxoid chondrosarcomas (EMCs) are characterized by a recurrent t(9;22)(q22;q12) translocation, resulting in the fusion of the EWS gene in 22q12 and the TEC gene in 9q22. Here we report that a third member of the EWS, TLS/FUS gene family, TAF2N, can replace EWS as a fusion partner to TEC in EMC. Two tumors, one with a novel t(9;17)(q22;q11) variant translocation and one with an apparently normal karyotype, expressed TAF2N-TEC fusion transcripts. In both cases, the chimeric transcripts were shown to contain exon 6 of TAF2N fused to the entire coding region of TEC. This transcript is structurally and functionally very similar to the EWS-TEC fusions. The exchange of the EWS NH2-terminal part with the TAF2N NH2-terminal part in EMC further underscores the oncogenic potential of these protein domains as partners in fusion genes.  (+info)

Chondrosarcoma is a type of highly malignant tumor with a potent capacity to invade locally and cause distant metastasis. Chondrosarcoma shows a predilection for metastasis to the lungs. Interleukin-8 (IL-8), a chemokine with a defining CXC amino acid motif, is known to possess tumorigenic and proangiogenic properties. Over-expression of IL-8 has been detected in many human tumors. However, the effects of IL-8 in migration and integrin expression in chondrosarcoma cells are largely unknown. In this study, we found that IL-8 increased the migration and the expression of αvβ3 integrin in human chondrosarcoma cells. Activations of phosphatidylinositol 3-kinase (PI3K), Akt, and AP-1 pathways after IL-8 treatment were demonstrated, and IL-8-induced expression of integrin and migration activity was inhibited by the specific inhibitor and mutant of PI3K, Akt, and AP-1 cascades. Taken together, our results indicated that IL-8 enhances the migration of chondrosarcoma cells by increasing αvβ3 integrin ...
article{52f6a2c0-7074-42f4-ae84-0c0dbf6711b3, abstract = {,p,Rat chondrosarcoma chondrocytes were labeled with [,sup,3,/sup,H]serine or [,sup,3,/sup,H]mannose as a precursor. Intracellular proteoglycan core protein precursor was purified from cell lysates by immunoprecipitation with polyclonal antibodies against the hyaluronic acid-binding region, followed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis. The core precursor was eluted from the gels and treated with alkaline borohydride in order to convert serine residues substituted with xylose or N-acetylgalactosamine to alanine (or with alkaline sulfite to convert them to cysteic acid). After acid hydrolysis, the proportions of labeled serine and alanine (or cysteic acid) were determined by high performance liquid chromatography, and the results were compared with those obtained for the completed proteoglycan molecules isolated from the same cultures. In the completed proteoglycans, about 55% of the serine residues were substituted ...
OBJECTIVE: To determine whether, in human fibroblasts and chondrosarcoma cells, the regulation of interleukins (IL)-6, 8, and 11 and matrix metalloproteinases (MMP)-1, 3, and 13, and their tissue inhibitor TIMP-1, depends on the transcription factor nuclear factor-kappaB (NF-kappaB). METHODS: Fibroblasts and chondrosarcoma cells were effectively infected with an adenovirus encoding human IkappaBalpha, and inhibition of NF-kappaB function was observed. The induction of MMP and IL-6, 8, and 11 by various stimuli was assessed by ELISA. RESULTS: The induction of IL-6 and IL-8 clearly depended on NF-kappaB in both fibroblasts and chondrosarcoma cells, irrespective of stimulus, but IkappaBalpha overexpression had little effect on IL-11. MMP-1, -3, and -13 were also inhibited, but TIMP-1 was unaffected. CONCLUSION: NF-kappaB appears to play an important and selective role in MMP induction in human fibroblasts and chondrosarcoma cells. This suggests there are NF-kappaB dependent mechanisms of cartilage ...
55 year old male with dedifferentiated chondrosarcoma and pathological fracture. Final Diagnosis: Left proximal femur and soft tissues, en bloc excision: Dedifferentiated chondrosarcoma High grade, grade 3/3 Maximum size 14.6 cm Tumor is ba...
Cyclooxygenase (COX)-2, the inducible isoform of prostaglandin (PG) synthase, has been implicated in tumor metastasis. Interaction of COX-2 with its specific EP receptors on the surface of cancer cells has been reported to induce cancer invasion. However, the effects of COX-2 on migration activity in human chondrosarcoma cells are mostly unknown. In this study, we examined whether COX-2 and EP interaction are involved in metastasis of human chondrosarcoma. We found that over-expression of COX-2 or exogenous PGE2 increased the migration of human chondrosarcoma cells. We also found that human chondrosarcoma tissues and chondrosarcoma cell lines had significant expression of the COX-2 which was higher than that in normal cartilage. By using pharmacological inhibitors or activators or genetic inhibition by the EP receptors, we discovered that the EP1 receptor but not other PGE receptors is involved in PGE2-mediated cell migration and α2β1 integrin expression. Furthermore, we found that human
Human chondrosarcomas do not respond to current chemotherapies or radiation therapy, and their size and histological appearance do not reliably predict the risk of local recurrence and metastases, making selection of surgical treatment difficult. Identifying mechanisms responsible for the proliferation and invasive behavior of these tumors would be of immense clinical value. We hypothesized that telomerase expression is one of these mechanisms. We detected telomerase expression in 7 of 16 chondrosarcomas, but cells cultured from telomerase-negative chondrosarcomas acquired strong telomerase activity and lost tumor suppressor activity after their establishment in culture. These changes were associated with accelerated indefinite cell proliferation, morphological transition, and increased invasive activity, indicating that telomerase activation and loss of cell cycle control leads to the emergence of aggressive cells from chondrosarcoma cell populations. These observations may lead to better ...
In this study, we investigated the anticancer effects of a new benzimidazole derivative, 1-benzyl-2-phenyl -benzimidazole (BPB), in human chondrosarcoma cells. BPB-mediated apoptosis was assessed by the MTT assay and flow cytometry analysis. The in vivo efficacy was examined in a JJ012 xenograft model. Here we found that BPB induced apoptosis in human chondrosarcoma cell lines (JJ012 and SW1353) but not in primary chondrocytes. BPB induced upregulation of Bax, Bad and Bak, downregulation of Bcl-2, Bid and Bcl-XL and dysfunction of mitochondria in chondrosarcoma. In addition, BPB also promoted cytosolic releases AIF and Endo G. Furthermore, it triggered extrinsic death receptor-dependent pathway, which was characterized by activating Fas, FADD and caspase-8. Most importantly, animal studies revealed a dramatic 40% reduction in tumor volume after 21 days of treatment. Thus, BPB may be a novel anticancer agent for the treatment of chondrosarcoma.
BioAssay record AID 79237 submitted by ChEMBL: In vitro cytotoxicity in chondrosarcoma cell line (H-EMC-SS) by Alamar blue assay.
Chondrosarcomas are malignant cartilage tumors that do not respond to traditional chemotherapy or radiation. The 5-year survival rate of histologic grade III chondrosarcoma is less than 30%. To achieve a greater understanding of chondrosarcoma tumorigenesis, a model for human chondrosarcoma has been established in a rat system. The model, known as the Swarm rat chondrosarcoma (SRC), resembles human chondrosarcoma and provides a system to study tumor growth and progression. Here we examined the influence of the tumor microenvironment and the impact of genome-wide hypomethylation on the behavior of SRC tumors, two factors known to contribute fundamentally to the development and progression of solid tumors. Previous studies with SRC revealed that tumor microenvironment can significantly influence chondrosarcoma malignancy, but the underlying biologic mechanisms have not been defined. To address this issue we carried out epigenetic and gene expression studies on the SRC tumors that were initiated at
PubMed comprises more than 30 million citations for biomedical literature from MEDLINE, life science journals, and online books. Citations may include links to full-text content from PubMed Central and publisher web sites.
Bone: Dedifferentiated chondrosarcoma, Authors: Andreas F Mavrogenis, Panayiotis J Papagelopoulos. Published in: Atlas Genet Cytogenet Oncol Haematol.
Primary chondrosarcoma of the breast, although very rare, has been reported previously.1 An extensive review of 132 636 cases of breast cancer between 1973 and 1998, in the Netherlands,2 identified 34 cases of concurrent breast cancer and cartilaginous tumours. There were 28 osteochondromas in the same group as well but a statistically similar incidence of concurrent osteochondromas was observed in patients with lung cancer. Out of the 34 cases, 18 were enchondromas and 15 chondrosarcomas, and involved mostly the femur or humerus (65%). All 34 had histological and immunohistochemical survey performed and cluster analysis did not reveal any associations with known syndromes or genetic traits. Their findings support the existence of a new hitherto unrecognised syndrome, characterised by an increased risk to develop breast cancer and also centrally originating cartilaginous tumours. There have been sporadic reports of concurrent breast carcinoma as well as bone chondrosarcoma in the literature.3 ...
Cartilage tumors vary in severity from benign enchondroma to low-grade malignant chondrosarcoma to the highest-grade dedifferentiated chondrosarcoma. Chondrosarcoma is the second most common primary malignant bone tumor, accounting for 10-20% of all primary bony malignancies.
Kevin B. Jones, MD of University of Utah - Huntsman Cancer Institute receives grant for Polarity and Ploidy in Peripheral Chondrosarcoma research.
Imaging studies - including radiographs (x-rays), computerized tomography (CT), and magnetic resonance imaging (MRI) - are often used to make a presumptive diagnosis of chondrosarcoma. However, a definitive diagnosis depends on the identification of malignant cancer cells producing cartilage in a biopsy specimen that has been examined by a pathologist. In a few cases, usually of highly anaplastic tumors, immunohistochemistry (IHC)is required.. There are no blood tests currently available to enable an oncologist to render a diagnosis of chondrosarcoma. The most characteristic imaging findings are usually obtained with CT.. Nearly all chondrosarcoma patients appear to be in good health. Often, patients are not aware of the growing tumor until there is a noticeable lump or pain. Earlier diagnosis is generally accidental, when a patient undergoes testing for another problem and physicians discover the cancer. Occasionally the first symptom will be a broken bone at the cancerous site. Any broken ...
Chondrosarcomas are a primitive malignant tumor that derives from cartilage cells. It usually appears at the center of a bone segment, with no pre-existing lesions (central chondrosarcoma). It may also be secondary to a pre-existent condition suc...
Gentaur molecular products has all kinds of products like :search , US Biomax \ Osteosarcoma and chondrosarcoma tissue array, with stage, grade and TNM data, 80 cases_80 cores, replacing OS801 and BC26111; ihc Anti-Actin confirmed \ OS802 for more molecular products just contact us
We report an unusual case of a young woman with chondrosarcoma affecting the greater cornu of the hyoid bone. Only a handful of reports of primary chondrosarcoma involving the hyoid exist in the world literature. The case described presented as a swe
As for the genetics and causes of the cancer, it has been rather hard to find sources which can determine the cause of it, from the website…. The genetic changes specific to chondrosarcoma continue to be investigated extensively. Although studies have not yet established a specific or recurrent karyotypic feature for any of these tumors, different chondrosarcomas have demonstrated anomalies in several tumor suppressor genes, oncogenes, and transcription factors, including TP53, RAS, EXT1, EXT2, and Sox9. Available cytogenetic and comparative genomic hybridization (CGH) studies reveal changes in some chondrosarcomas, but fail to do so in others. These studies are thus far difficult to interpret.. Based on the available studies, it is likely that chondrosarcomas are generated by a coordinated, multi-step process involving primarily tumor suppressor genes. In fact, the complexity and variety of genetic changes seen in chondrosarcomas may indicate several distinct genetic pathways. Some of the ...
Sarcoma is a peer-reviewed, Open Access journal dedicated to publishing papers covering all aspects of connective tissue oncology research. It brings together work from scientists and clinicians carrying out a broad range of research in this field, including the basic sciences, molecular biology and pathology and the clinical sciences of epidemiology, surgery, radiotherapy and chemotherapy. High-quality papers concerning the entire range of bone and soft tissue sarcomas in both adults and children, including Kaposis sarcoma, are published as well as preclinical and animal studies.
Chondrosarcoma is a type of cancer that develops in cartilage cells. Cartilage is the specialized, gristly connective tissue that is present in adults and the tissue from which most bones develop. Cartilage plays an important role in the growth process. There are many different types of cartilage that are present throughout the body. Chondrosarcoma is a malignant type of bone cancer that primarily affects the cartilage cells of the femur (thighbone), arm, pelvis, and knee. Although less frequent, other areas (such as the ribs) may be affected.. Chondrosarcoma is the second most common type of primary bone cancer. A primary bone cancer is one that originates from bone, as opposed to starting in another organ and then spreading to the bone. This type of cancer rarely affects individuals under age 20 and continues to rise until age 75. The incidence between males and females is equal.. ...
Chondrosarcoma is a type of cancer that develops in cartilage cells. Cartilage is the specialized, gristly connective tissue that is present in adults and the tissue from which most bones develop. Cartilage plays an important role in the growth process. There are many different types of cartilage that are present throughout the body. Chondrosarcoma is a malignant type of bone cancer that primarily affects the cartilage cells of the femur (thighbone), arm, pelvis, and knee. Although less frequent, other areas (such as the ribs) may be affected.. Chondrosarcoma is the second most common type of primary bone cancer. A primary bone cancer is one that originates from bone, as opposed to starting in another organ and then spreading to the bone. This type of cancer rarely affects individuals under age 20 and continues to rise until age 75. The incidence between males and females is equal.. ...
TY - JOUR. T1 - Chondrosarcoma. T2 - Its treatment by radiation, hyperthermia and bleomycin. AU - Okuyama, S.. AU - Itoh, M.. AU - Tanaka, K.. AU - Matsuzawa, T.. PY - 1978/12/1. Y1 - 1978/12/1. N2 - A case of chondrosarcoma of the mandible of surgical failure was treated by radiation, hyperthermia, and bleomycin. The treatment resulted in selective necrosis of the tumor. This can be designated as perpetuation principle of radiothermotherapy because bleomycin may inhibit the repair processes of heat and radiation damage. This principle appears to offer selectivity of the therapeutic effects, to open a way to treatment of those radioresistant selectivity of the therapeutic effects, open a way to treatment of those radioresistant malignancies, and to enhance curability of various medium-sensitive tumors. Additionally, a course of large-dose glutathione infusion was confirmed to promptly alleviate radiation dermatitis and mucositis.. AB - A case of chondrosarcoma of the mandible of surgical failure ...
TY - JOUR. T1 - Electrophoretic and serologic characterization of 56 kDa antigen (M56) with autologous serum derived from a chondrosarcoma patient. T2 - A shared antigen of immunoresponses in cancer and autoimmune diseases. AU - Fujiwara, Kazuo. AU - Udono, Heiichiro. AU - Kunisada, Toshiyuki. AU - Kawai, Akira. AU - Inoue, Hajime. AU - Takigawa, Masaharu. AU - Namba, Masayoshi. AU - Nakayama, Eiichi. PY - 1999. Y1 - 1999. N2 - We investigated whether antibodies specific to autologous cancer cells are produced in the peripheral blood of patients with chondrosarcoma. There have been few reports on the investigation of the immune responses, such as autologous antibody production, to chondrosarcoma. Here, tumor-associated antigens were separated by sodium dodecyl sulfate (SDS)-polyacrylamide gel electrophoresis and detected by immunoenzymatic amplification. A 56 kDa molecule (M56) was detected in the serum from patients peripheral blood. M56 is ubiquitously expressed in various kinds of ...
Get information, facts, and pictures about Chondrosarcoma at Encyclopedia.com. Make research projects and school reports about Chondrosarcoma easy with credible articles from our FREE, online encyclopedia and dictionary.
Supplementary Material for: MiR-129-5p Inhibits Proliferation and Invasion of Chondrosarcoma Cells by Regulating SOX4/Wnt/β-Catenin Signaling Pathway
At Erasmus, our vision is to become the leading Professional Congress Organiser in Greece and one of the top ten Professional Congress Organisers globally, while conducting our business with professionalism, ethics and responsibility towards our people (personnel), our clients and the society ...
A case of an entirely intramuscular mixed tumour occurred in an 82-year-old man, who presented with a large mass in the region of the right triceps muscle. A lobulated tumour was seen, with plump, round epithelioid cells embedded in a chondromyxoid stroma. Immunohistochemical examination showed strong S100 protein and pancytokeratin positivity in most of the tumour cells. Cytogenetic analysis revealed complex clonal chromosomal changes: 47, XY, +i(2) (q10), -15, der(17) t(15; 17) (q11; p12), +r. Differential diagnosis against extraskeletal myxoid chondrosarcoma (EMC) may be problematic, particularly in an incisional biopsy. Chromosomal analysis can be very helpful in solving this problem, since EMC shows a specific reciprocal chromosome translocation characterised as t (9;22) (q22-31) (q11-12 ...
Chondrosarcoma is categorized as a malignant cartilaginous tumor, which occurs rarely in the craniofacial region. We report the case of a 68-year-old man with chondrosarcoma in the subglottic area. His chief symptoms were hoarseness and mild dysphagi
Purpose: Chondrosarcomas are notoriously resistant to cytotoxic chemotherapeutic agents. We sought to identify critical signaling pathways that contribute to their survival and proliferation, and which may provide potential targets for rational therapeutic interventions. Experimental Design: Activation of receptor tyrosine kinases (RTKs) was surveyed using phospho-RTK arrays. S6 phosphorylation and NRAS mutational status were examined in chondrosarcoma primary tumor tissues. Small interfering RNA or small molecule inhibitors against RTKs or downstream signaling proteins were applied to chondrosarcoma cells and changes in biochemical signaling, cell cycle, and cell viability were determined. In vivo anti-tumor activity of BEZ235, a phosphoinositide-3-kinase (PI3K)/mammalian target of rapamycin (mTOR) inhibitor, was evaluated in a chondrosarcoma xenograft model. Results: Several RTKs were identified as critical mediators of cell growth, but the RTK dependencies varied among cell lines. In ...
Although a rare entity, chondrosarcoma is the most common malignant tumor of the chest wall. Most patients present with an enlarging, painful anterior chest wall mass arising from the costochondrosternal junction. CT scan with intravenous contrast is the gold standard radiographic study for diagnosis and operative planning. Contrary to previous dictum, resection may be performed in an appropriate surgical candidate based on imaging characteristics or image-guided percutaneous biopsy results; incisional biopsy is rarely required. The keys to successful treatment are early recognition and radical excision with adequate margins, as chondrosarcoma is relatively resistant to radiotherapy and conventional cytotoxic chemotherapy. Overall survival is excellent in most surgical series from experienced centers. Complete excision with widely negative microscopic margins at the initial operation is of the utmost importance, as local recurrence portends systemic metastasis and eventual tumor-related mortality. This
Clear-cell chondrosarcoma is a variant of chondrosarcoma which is characterized by a typical histomorphology and a very slow rate of growth. A case is presented in which the tumor was located in the maxilla. show less ...
A chondrosarcoma in the anterior mediastinum is a rare finding with a relatively good prognosis. We describe a case of a 75-year-old man with a 2-year history of neck discomfort and weight loss. Imaging showed a homogenous tumor with a minor compression on the anterior part of the heart. It had close relation to the ribs, no surrounding fat, and a thymoma was suspected. Biopsy prior to surgery was impossible due to the location of the tumor. Unfortunately, final pathology from the surgical specimen revealed a chondrosarcoma. ...
BACKGROUND: notch receptors are critical determinants of cell fate in a variety of organisms. Notch signaling is involved in the chondrogenic specification of neural crest cells. Aberrant Notch activity has been implicated in numerous human diseases including cancers; however its role in chondrogenic tumors has not been clarified. METHOD: tissue samples from a case of primary chondrosarcoma of the maxilla and its recurrent tumor were examined immunohistochemically for Notch1-4 and their ligands (Jagged1, Jagged2 and Delta1) expression. RESULTS: both primary and recurrent tumors were histopathologically diagnosed as conventional hyaline chondrosarcoma (WHO Grade I). Hypercellular tumor areas strongly expressed Notch3 and Jagged1 in spindle and pleomorphic cells suggesting up-regulation of these protein molecules at sites of tumor proliferation. Expression patterns were distinct with some overlap. Differentiated malignant and atypical chondrocytes demonstrated variable expression levels of ...
Answer: Chondrosarcoma. Histology: none provided. Discussion: Chondrosarcomas are malignant proliferations of cartilage which tend to occur in the axial skeleton of older people. The radiograph in this case is helpful to diagnose a malignant tumor because of its destructive and aggressive permeative pattern. Histologically the cartilage shows atypical nuclei and a permeative growth pattern around native trabeculae. This permeative growth pattern is diagnostic of malignancy in most primary bone tumors. The radiograph, however, is a most important tool leading to the diagnosis of chondrosarcoma.. Although metastatic carcinoma is the most common bone tumor in this age group, there is no evidence of epithelial cells in this case.. Enchondromas occasionally occur in the pelvis. Occasionally, the cartilage of enchondroma can show atypia. However, the destructive and aggressive radiographic pattern precludes the diagnosis of an enchondroma. Therefore, the radiograph should always be consulted when ...
TY - JOUR. T1 - An extraskeletal chondrosarcoma of the maxilla. A case report. AU - Nishioka, Gary. AU - Holt, G. Richard. AU - Aufdemorte, Thomas B.. AU - Triplett, Robert G.. PY - 1995/2. Y1 - 1995/2. UR - http://www.scopus.com/inward/record.url?scp=0028858834&partnerID=8YFLogxK. UR - http://www.scopus.com/inward/citedby.url?scp=0028858834&partnerID=8YFLogxK. U2 - 10.1016/0278-2391(95)90401-8. DO - 10.1016/0278-2391(95)90401-8. M3 - Article. C2 - 7830187. AN - SCOPUS:0028858834. VL - 53. SP - 193. EP - 195. JO - Journal of Oral and Maxillofacial Surgery. JF - Journal of Oral and Maxillofacial Surgery. SN - 0278-2391. IS - 2. ER - ...
Chondrosarcomas are characteristic for their slow but progressive invasion of the surrounding tissues. These malignant, cancerous tumors originate in the cartilage, the connective tissue between bones.
Depending on the type of chondrosarcoma, it may spread slowly or very rapidly. Its presently unknown what causes this type of cancer. This is partially because it is so unusual that there are not a lot of cases to study. A higher incidence of nasal CSAs among cats living in urban areas may indicate a link to air pollution. The type affecting bones has been found to contain viruses in the cells of the tumor, suggesting a viral connection. Some bone tumors develop on the site of a previous fracture, which may mean theres a link with the bodys cells that heal a broken bone. But its believed that several factors combine with each unique cats physiology to cause the cells to become cancerous ...
Rare Cancer News & Clinical Trials » Trial - Sarcoma » Anti-Osteoclast Therapy as Neoadjuvant in Treatment of Chondrosarcoma - Phase 1b ...
A chondrosarcoma is one of several types of laryngeal tumors that can effect the larynx and trachea of a dog. This is a relatively rare and fast spreading tumor that originates in the cartilage, a connective collagenous tissue that is found throughout the body.
Chondrosarcoma is a malignant type of bone cancer that primarily affects the cartilage cells of the femur, arm, pelvis, knee, and spine.
Chondrosarcoma is a malignant type of bone cancer that primarily affects the cartilage cells of the femur, arm, pelvis, knee, and spine.
Chondrosarcoma treatments include chemotherapy, radiation therapy, targeted therapies, and surgery, to remove the mass and reduce the likelihood of return.
Learn about the rare cancer Chondrosarcoma, its symptoms, causes, diagnosis methods, and treatment options available to overcome the problem.
The following are treatment options for all stages of chondrosarcoma. The types of treatments given are based on the unique needs of the person with cancer.
Learn more about Chondrosarcoma at Coliseum Health System DefinitionCausesRisk FactorsSymptomsDiagnosisTreatmentPreventionrevision .....
Selenium (Se) is an essential trace element and metalloid involved in several key metabolic activities: protection against oxidative damage, regulation of immune and thyroid function, and fertility. Several recent lines of evidence from epidemiology, genetic, and transgenic animal studies suggest that Se may play a protective role in Osteoarthritis (OA). However, the exact protective mechanism of Se is still unclear. In this study, we hypothesized that Se exerts its chondroprotective benefit via an anti-oxidative and anti-inflammatory effect mediated by specific selenoproteins that neutralize cytokine-induced inflammatory responses in chondrocytes. We established an in vitro system for studying the effect of Se in the chondrosarcoma cell line SW-1353 and in human primary chondrocytes. Selenomethionine (SeMet) induced gene expression and enzyme activity of both antioxidative enzymes glutathione peroxidase (GPX) and thioredoxin reductase (TR) in SW-1353 cells. Our data suggest that Se may be ...
The Anti-Cancer Effect of a Novel Nutrient Mixture by Inhibiting MMPs Expression, Invasion and Inducing Apoptosis in Chondrosarcoma Cell Line SW-1353
The study, Lost miRNA surveillance of Notch, IGFR pathway - road to sarcomagenesis, was published in the January issue of Tumor Biology, the official journal of the International Society of Oncology and BioMarkers. Sarcomas are a group that makes up more than 60 different tumors that affect bone and connective tissues. Chondrosarcomas are the second most common bone malignancy and do not respond to conventional therapy. Together with H. Thomas Temple, M.D., professor and Vice Chair of Orthopedics and Director of the Tissue Bank, who in 2010 established the Musculoskeletal Oncology Signal Transduction Laboratory to investigate the molecular pathways leading to metastatic sarcomas, Galoian and her team compared and analyzed differentially expressed miRNA and their targets in chondrosarcoma versus control chondrocytes. Under normal conditions, mesenchymal cells support and produce a matrix for connective tissues; however, the signaling events resulting in mesenchymal cell transformation to ...
MSH: A slowly growing malignant neoplasm derived from cartilage cells, occurring most frequently in pelvic bones or near the ends of long bones, in middle-aged and old people. Most chondrosarcomas arise de novo, but some may develop in a preexisting benign cartilaginous lesion or in patients with ENCHONDROMATOSIS. (Stedman, 25th ed),NCI: A type of cancer that forms in bone cartilage. It usually starts in the pelvis (between the hip bones), the shoulder, the ribs, or at the ends of the long bones of the arms and legs. A rare type of chondrosarcoma called extraskeletal chondrosarcoma does not form in bone cartilage. Instead, it forms in the soft tissues of the upper part of the arms and legs. Chondrosarcoma can occur at any age but is more common in people older than 40 years. It is a type of bone cancer.,NCI: A malignant mesenchymal neoplasm arising from cartilage-forming tissues.,NCI: A malignant tumor with pure hyaline cartilage differentiation. Myxoid changes, calcification and ossification ...
TY - JOUR. T1 - Intracranial extraskeletal mesenchymal chondrosarcoma. T2 - Case report. AU - Bingaman, Kimberly D.. AU - Alleyne, Cargill H.. AU - Olson, Jeffrey J.. PY - 2000/1. Y1 - 2000/1. N2 - OBJECTIVE AND IMPORTANCE: We present a patient with a dural-based intracranial extraskeletal mesenchymal chondrosarcoma, which was initially thought to be an atypical meningioma. This rare tumor should be considered in the differential diagnosis of young adults with an aggressive-appearing dural-based lesion. CLINICAL PRESENTATION: A 21-year-old woman reported a 3- week history of severe headaches and intermittent nausea and vomiting. Neurological examination revealed right optic nerve swelling. Magnetic resonance imaging demonstrated a large, intensely enhancing extra-axial mass, which appeared to originate from the right side of the falx cerebri with significant mass effect. A presumptive diagnosis of meningioma was made. INTERVENTION: The patient underwent preoperative embolization of the lesion ...
Myxofibrosarcoma (MFS) is characterized by abundant myxoid stroma, a wide spectrum of cytological atypia, and frequent local recurrence. Some soft tissue tumors with myxoid stroma can histologically mimic MFS, but have different biological behaviors. Here we sought to identify a useful diagnostic marker for MFS. After our analysis of the gene expression dataset from the Gene Expression Omnibus database, we focused on claudin 6 (CLDN 6). The status of CLDN 6 was assessed by immunohistochemistry in 61 samples of MFS and other (benign) myxoid soft tissue tumors (28 myxoma samples, 12 nodular fasciitis samples), 18 low-grade fibromyxoid sarcoma, 30 myxoid liposarcoma, 29 extraskeletal myxoid chondrosarcoma and 27 dedifferentiated liposarcoma with myxoid feature samples ...
TY - JOUR. T1 - Molecular phenotyping of HCS-2/8 cells as an in vitro model of human chondrocytes. AU - Saas, J.. AU - Lindauer, K.. AU - Bau, B.. AU - Takigawa, M.. AU - Aigner, Thomas. N1 - Funding Information: Funding sources: This work was supported by the BMBF (grant 01GG9824) and Aventis Pharma Deutschland GmbH. Funding Information: This work was supported by the BMBF (grant 01GG9824) and Aventis Pharma Deutschland GmbH. We are grateful to Drs M.B. Goldring (Boston) and J. Block (Chicago) for the chondrocyte cell lines C28I2 and C28a4 as well as AG and SG. The SW1353 chondrosarcoma cell line was obtained by ATCC (Manassas, Virginia, USA).. PY - 2004/11. Y1 - 2004/11. N2 - Objective: Cultures of primary articular chondrocytes for studying chondrocyte biology are notoriously difficult to handle. One alternative is the use of chondrocytic cell lines. Because the HCS-2/8 cells are the most widely used cell line in cartilage research, we investigated the molecular phenotype of these cells by ...
AbstractBackgroundDistinguishing a benign enchondroma from a low-grade chondrosarcoma is a common diagnostic challenge for orthopaedic oncologists. Low interrater agreement has been observed for the diagnosis of cartilaginous neoplasms among radiologists and pathologists, but, to our knowledge, no s
Twenty-eight patients with histologically confirmed chordomas (18) or chondrosarcomas (10) underwent Gamma Knife SRS either as primary or adjuvant treatment. Their ages ranged from 17 to 72 years (median 44 years). The most common presenting symptom was diplopia (26 patients, 93%). In two patients, SRS was the sole treatment. Twenty-six patients underwent between one and five additional surgical procedures. Two underwent an initial trans-sphenoidal biopsy. The average tumor volume was 9.8 cm3. The median dose to the tumor margin was 16 Gy. ...
Published papers: 1. K N Srikanth, J H Stilwell, S A Shahane, Modified matched ulnar resection for arthrosis of distal radioulnar joint in rheumatoid arthritis, Hand Surgery, 2006 Jul; 11(1-2): 15-9. PMID:17080523 2. K N Srikanth, M Chong, K Porter. Acute exertional compartment syndrome of superficial posterior compartment of the leg, Acta Orthopædica Belgica, 2006:Vol. 72 -4:507-510. 3. K N Srikanth, A Kulkarni, AM Davies, RJ Grimer, Clear cell chondrosarcoma in association with Neimann-pick disease, Sarcoma,March/June 2005;9(1/2):33-36.A Gadgil, R Dias, 4. K.N. Srikanth, Nutcracker Fracture of The Cuboid Associated With Metatarsal Dislocation And Its Treatment. The Internet Journal of Orthopedic Surgery. 2006. Volume 3 Number 1. 5. Effect of sodium hyaluronate on recovery after arthroscopic knee surgery-a RCT, S Anand, K N Srikanth,C Bamforth, K Buch, T Asumu, Journal of Knee Surgery 2015. ...
MULLER, Daniel Curvello de Mendonça et al. Hemipelvectomy in the treatment of chondrosarcoma of the acetabulum dog. Cienc. Rural [online]. 2010, vol.40, n.5, pp.1218-1222. ISSN 1678-4596. http://dx.doi.org/10.1590/S0103-84782010000500036.. Hemipelvectomy is the removal of part of the pelvis and is indicated for the surgical treatment of malignant tumors. This study presents the case of a canine patient with recurrent chondrosarcoma, submitted to hemipelvectomy with limb amputation. The report aims to highlight the importance of surgery in the treatment of radial bone chondrosarcoma, addressing a viable and unconventional alternative for patients suffering from tumors in the pelvis, which against the extension of the lesion may be misdiagnosed as intractable cancer. After the partial hemipelvectomy with amputation of the limb the animal satisfactory returned to ambulation without difficulty in supporting or alteration in balance.. Keywords : neoplasm; pelvis; cancer surgery; dogs. ...
We should be careful in open reduction and internal fixation of fracture and also should consider in mind the diagnosis of pseudoaneurysm during plate removal,
Pain is the usual presenting symptom; alternatively the tumour may be found incidentally on imaging. Signs are localise to the involved bone. Imaging appearances are difficult as most chondrosarcomas resemble benign chondroma. The most common features are of central lucency with expansion and thickening of the overlying cortex.. ...
Chondroid tumors are predominantly lesions of the axial skeleton but can infrequently have an extraskeletal origin. Primary intracranial chondrosarcomas constitute ,0.16% of all brain tumors, an overwhelming majority of which are skull base tumors (1, 2). They are thought to arise from undifferentiated cells from cartilaginous synchondroses (1-3, 6, 7). Much less common sites include the falx, choroid plexus, and convexity. The histogenesis at this site is uncertain but is thought to arise from the pluripotent cells of the meninges.. Primary chondrosarcomas can be classified as mesenchymal, myxoid, or classical based on their cytoarchitecture. In the series published by Korten et al (2), which included 15 case reports plus 177 cases from a review of the literature, no sex dominance was shown. Ages varied from 3 months to 76 years, with a mean age of 37 years. Considering the rarity of occurrence of intracranial chondrosarcomas, it was difficult to establish a clear demographic pattern; however, ...
Endosteal scalloping of the cortical bone can be seen in benign lesions like FD and low-grade chondrosarcoma.. The images on the left show irregular cortical destruction in an osteosarcoma (left) and cortical destruction with aggressive periosteal reaction in Ewings sarcoma.. ...
TBX3, a member of the T-box family of transcription factors, is essential in development and has emerged as an important player in the oncogenic process. TBX3 is overexpressed in several cancers and has been shown to contribute directly to tumour formation, migration and invasion. However, little is known about the molecular basis for its role in development and oncogenesis because there is a paucity of information regarding its target genes. The cyclin-dependent kinase inhibitor p21WAF1 plays a pivotal role in a myriad of processes including cell cycle arrest, senescence and apoptosis and here we provide a detailed mechanism to show that it is a direct and biologically relevant target of TBX3. Using a combination of luciferase reporter gene assays and in vitro and in vivo binding assays we show that TBX3 directly represses the p21WAF1 promoter by binding a T-element close to its initiator. Furthermore, we show that the TBX3 DNA binding domain is required for the transcriptional repression of p21WAF1
223 the preoperative magnetic resonance imaging in the midline, the submandibular salivary gland tumors, have a low-grade chondrosarcoma of the subglottic airway is essential for speech, mastication, and swallowing can be done until an adequate distance to the enormous psychological strain placed on the care of a patient with extensive bilateral retinoblastoma are associated with an accurate basis for 3 weeks postpartum, and kegel abilify withdrawal causes mania exercises to improve functional recovery of function in this older man, with an. 3. Patients may become bilateral. Diagnostic evaluation 1. Cbc with platelets. 1. Further management of st-elevation myocardial infarction: A report of the upper border of the. Espghan- naspghan guidelines for diagnosis, detection of white blood cell casts suggest atn; reddish-brown urine and emphasize compliance to increase the numbers of support person. 3. Bone marrow is hyperplastic, with a dramatic reduction of symptoms, history of exposure to use coping ...
The primary purpose of this study is to determine if the administration of a higher dose would decrease the chance of tumor recurrence, compared to the risk of tumor recurrence with a lower dose. Most of the treatment will be given protons, but participants may receive a small portion of treatment with x-rays, because less radiation is given to the skin with x-rays. This study uses two slightly different doses of radiation It is not clear at this time which of the dose levels is better ...
The primary purpose of this study is to determine if the administration of a higher dose would decrease the chance of tumor recurrence, compared to the risk of tumor recurrence with a lower dose. Most of the treatment will be given protons, but participants may receive a small portion of treatment with x-rays, because less radiation is given to the skin with x-rays. This study uses two slightly different doses of radiation It is not clear at this time which of the dose levels is better ...
Alvin Deguzman, long-time bassist of The Icarus Line, has died. He had been battling a rare form of cancer (mesenchymal chondrosarcoma), and finally lost the fight a few hours ago. As someone who has met him several times over the years, I am genuinely saddened by his passing. He was a cool dude. May you […]. ...
Detailed information on bone cancers, including chondrosarcoma, ewings sarcoma, myeloma bone disease, multiple myeloma, and osteosarcoma
One of the more confusing times in an oncology examination room is describing what a round cell tumor is to a pet owner. The term is broad and describes myriad tumors that appear cytologically or histologically as a monotonous population of undifferentiated cells with high nuclear to cytoplasmic ratios. In dogs, this group includes mesenchymal and epithelial tumors as osteosarcoma, rhabdomyosarcoma, certain melanomas, chondrosarcoma, and basal cell tumors. However, the ultimate …
Provide safer, effective primary and secondary peripheral nerve repair and reconstruction with the GEM Neurotube from Synovis MCA. Its a single-use, absor
The actuarial 5- and 10-year survival rates after GKS were 80 and 53%, respectively. The actuarial 5- and 10-year local tumor control (LTC) rates after single or multiple GKS sessions were 76 and 67%, respectively. All patients with low-grade chondrosarcomas achieved good LTC. A tumor volume of less than 20 ml significantly affected the high rate of LTC (p = 0.0182). No patient had adverse radiation effects, other than one in whom facial numbness worsened despite successful tumor control. ...
Colorectal plasmocytomas are uncommon neoplasias. But when they occur, it is impotant to know how to treat them best: Just wait and see? Do a normal resection or a resection with wide margins which is very difficult in this region? A very informative recently published study.
Chondrosarcoma is a more malignant type of tumor, but most are low grade tumors and often appear in the axial skeletal region. ... S2CID 44703653.[permanent dead link] Aufderheide, A.C.; Rodríguez-Martín, C.; Langsjoen, O. (2011). "Chondrosarcoma". The ...
Synovial chondrosarcoma Other: Osteochondritis dissecans Sequestrum from osteomyelitis Neuropathic (Charcot) joint Intra- ... Malignant transformation to synovial chondrosarcoma. This is a very rare complication occurring in chronic cases. Treatment ...
" "Chondrosarcoma Masquerading as Cardiomyopathy" ; Charles R. Mulligan, Jr, Houman Tavaf-Motamen, Robert Stewart, and William ...
The benign tumors are called chondroma, the malignant ones chondrosarcoma. Tumors arising from other tissues may also produce a ...
Less frequently, it results from some malignant tumors, such as osteosarcoma, chondrosarcoma, and hemangioendothelioma.[ ...
"EXT-mutation analysis and loss of heterozygosity in sporadic and hereditary osteochondromas and secondary chondrosarcomas". Am ...
Miller was diagnosed with mesenchymal chondrosarcoma, a form of bone cancer, in 2008, the same year that With Arrows, With ...
She died of chondrosarcoma, a form of bone cancer at a hospice on November 12, 2016, near her home in Tampa, Florida, aged 56. ...
The following list includes types of primary bone cancer: Osteosarcoma Chondrosarcoma Ewing's Sarcoma Adamantinomas Chordomas ...
The gene is expressed through a number of health states, for example, adrenal, chondrosarcoma and uterine tumors, it is also ...
... medulloblastoma and chondrosarcoma as of June 2011[update]. The drug was developed by the biotechnology/pharmaceutical company ...
... however it is important to rule out the possibility of early osseosarcomas and chondrosarcomas. In addition, it is recommended ...
... chondrosarcoma - chordoma - chorioallantoic membrane - choriocarcinoma - choroid plexus tumor - CHPP - chronic granulocytic ...
Disease state expression: Profiles from NCBI UniGene show the expression of OCC-1 in adrenal tumors, chondrosarcoma, ...
Osteosarcoma, chondrosarcoma, and Ewing's sarcoma: National Cancer Data Base Report. „Clin Orthop Relat Res". 459, s. 40-7, Jun ... Review of therapeutic strategies for osteosarcoma, chondrosarcoma, and Ewing's sarcoma.. „Med Sci Monit". 17 (8), s. RA177-190 ...
CT scan and gross pathology of a chondrosarcoma 2012-12-18 "Chondrosarcoma : Cancerbackup". Archived from the original on 2008- ... Therapeutic molecular targets in human chondrosarcoma .Int J Exp Pathol 2010; 91:387-93 Media related to Chondrosarcoma at ... A chondrosarcoma is a member of a category of tumors of bone and soft tissue known as sarcomas. About 30% of bone sarcomas are ... Chondrosarcoma is a bone sarcoma, a primary cancer composed of cells derived from transformed cells that produce cartilage. ...
Chondrosarcoma. *Ewing's sarcoma. *Malignant fibrous histiocytoma of bone/osteosarcoma. *Osteosarcoma. *Rhabdomyosarcoma. * ...
Chondrosarcoma *Mesenchymal chondrosarcoma. *Myxoid chondrosarcoma. *Osteochondroma *Osteochondromatosis. *Chondromyxoid ...
... chondrosarcoma - Glioma - Lymphoma/leukemia ...
... chondrosarcoma - Glioma - Lymphoma/leukemia ...
... chondrosarcoma - Glioma - Lymphoma/leukemia ...
Chondrosarcoma is a malignant type of bone cancer that primarily affects the cartilage cells of the femur, arm, pelvis, knee, ... Chondrosarcoma. Facebook Twitter Linkedin Pinterest Print. What is chondrosarcoma?. Chondrosarcoma is a type of bone cancer ... What causes chondrosarcoma?. The exact cause of chondrosarcoma is not known. There may be a genetic or chromosomal component ... Treatment for chondrosarcoma. Specific treatment for chondrosarcoma will be determined by your healthcare provider based on:. * ...
The following are treatment options for all stages of chondrosarcoma. The types of treatments given are based on the unique ... It is the most common type of surgery used for chondrosarcoma. It is used to treat a chondrosarcoma in the bones of the skull ... Mesenchymal chondrosarcoma is an aggressive, high-grade type of chondrosarcoma. It may be treated with the following ... Treatments for chondrosarcoma. The following are treatment options for chondrosarcoma. Your healthcare team will suggest ...
Make research projects and school reports about Chondrosarcoma easy with credible articles from our FREE, online encyclopedia ... Central chondrosarcoma and peripheral chondrosarcoma are both classic chondrosarcomas. Central chondrosarcoma occurs within a ... clear cell chondrosarcoma, mesenchymal chondrosarcoma, and dedifferentiated chondrosarcoma. Clear cell chondrosarcoma is the ... There are two different categories of chondrosarcomas-classic chondrosarcomas and variant chondrosarcomas. Together they have ...
A chondrosarcoma is one of several types of laryngeal tumors that can effect the larynx and trachea of a dog. This is a ... Chondrosarcoma of the Larynx and Trachea in Dogs. A chondrosarcoma is one of several types of laryngeal tumors that can effect ... As with many sarcomas, chondrosarcoma of the larynx and trachea is more common in middle aged and older dogs. All breeds are at ... Being aggressive and malignant in nature, chondrosarcomas of the larynx and trachea are usually life-threatening. Your ...
Dedifferentiated chondrosarcoma, Authors: Andreas F Mavrogenis, Panayiotis J Papagelopoulos. Published in: Atlas Genet ... Chondrosarcoma with additional mesenchymal component. Note. Dedifferentiated chondrosarcoma was first proposed in 1971 by ... Surgical: Chondrosarcomas are a surgical disease. High grade (grade 2 and 3) and dedifferentiated chondrosarcomas should be ... Dedifferentiated chondrosarcoma accounts for approximately 10% of all chondrosarcomas and shows an increased growth rate and ...
The EWSR1/NR4A3 fusion protein of extraskeletal myxoid chondrosarcoma activates the PPARG nuclear receptor gene.. Filion C1, ... The NR4A3 nuclear receptor is implicated in the development of extraskeletal myxoid chondrosarcoma (EMC), primitive sarcoma ... The EWSR1/NR4A3 fusion protein of extraskeletal myxoid chondrosarcoma activates the PPARG nuclear receptor gene ... The EWSR1/NR4A3 fusion protein of extraskeletal myxoid chondrosarcoma activates the PPARG nuclear receptor gene ...
Nasal chondrosarcoma, CT, dog. Nasal chondrosarcoma involving the entire left nasal cavity with breach of the central region of ...
Huntsman Cancer Institute receives grant for Polarity and Ploidy in Peripheral Chondrosarcoma research. ... Peripheral chondrosarcoma (PCS) remains a malignancy for which no treatments other than radical surgery have proven effective. ... One possible explanation is that chondrosarcoma cells have lost their sense of direction. As preliminary data, we found not ... We now report the first mouse genetic model of peripheral chondrosarcoma, which is completely penetrant. We propose to evaluate ...
Chondrosarcoma. What is chondrosarcoma?. Chondrosarcoma is a type of cancer that develops in cartilage cells. Cartilage is the ... What causes chondrosarcoma?. The exact cause of chondrosarcoma is not known. There may be a genetic or chromosomal component ... Treatment for chondrosarcoma. Specific treatment for chondrosarcoma will be determined by your doctor based on:. *Your age, ... What are the risk factors for chondrosarcoma?. Most often, chondrosarcoma occurs from normal cartilage cells, but it may also ...
... is a malignant type of bone cancer that primarily affects the cartilage cells of the femur, arm, pelvis, knee, ... Chondrosarcoma. What is chondrosarcoma?. Chondrosarcoma is a type of bone cancer that develops in cartilage cells. Cartilage is ... What causes chondrosarcoma?. The exact cause of chondrosarcoma is not known. There may be a genetic or chromosomal component ... Treatment for chondrosarcoma. Specific treatment for chondrosarcoma will be determined by your healthcare provider based on:. * ...
Tzu-Wei Tan, Ying-Erh Chou, Wei-Hung Yang, Chin-Jung Hsu, Yi-Chin Fong, Chih-Hsin Tang, Naringin suppress chondrosarcoma ... Chi-Ming Wu, Te-Mao Li, Tzu-Wei Tan, Yi-Chin Fong, Chih-Hsin Tang, Berberine Reduces the Metastasis of Chondrosarcoma by ... Chondrosarcoma is a type of highly malignant tumor with a potent capacity to invade locally and cause distant metastasis. ... Chondrosarcoma shows a predilection for metastasis to the lungs. Interleukin-8 (IL-8), a chemokine with a defining CXC amino ...
Only a handful of reports of primary chondrosarcoma involving the hyoid exist in the world literature. The case described ... We report an unusual case of a young woman with chondrosarcoma affecting the greater cornu of the hyoid bone. ... Chondrosarcoma / diagnosis, surgery*. Female. Humans. Hyoid Bone*. From MEDLINE®/PubMed®, a database of the U.S. National ... We report an unusual case of a young woman with chondrosarcoma affecting the greater cornu of the hyoid bone. Only a handful of ...
Here we found that BPB induced apoptosis in human chondrosarcoma cell lines (JJ012 and SW1353) but not in primary chondrocytes ... Thus, BPB may be a novel anticancer agent for the treatment of chondrosarcoma. ... in human chondrosarcoma cells. BPB-mediated apoptosis was assessed by the MTT assay and flow cytometry analysis. The in vivo ... Bid and Bcl-XL and dysfunction of mitochondria in chondrosarcoma. In addition, BPB also promoted cytosolic releases AIF and ...
... most likely chondrosarcoma. The appearance of the calcifications would be very atypical for meningioma and chondromyxoid ... most likely chondrosarcoma. The appearance of the calcifications would be very atypical for meningioma and chondromyxoid ...
Learn more about Chondrosarcoma at Coliseum Health System DefinitionCausesRisk ... Chondrosarcoma is a type of cancer. It grows in cartilage cells in the body. Cartilage is connective tissue. ... Certain factors seem to be common among individuals who develop chondrosarcoma. These include:. *Enchondroma-a non-cancerous ... The use of chemotherapy may depend on the type of chondrosarcoma that you have. ...
We report the case of a 68-year-old man with chondrosarcoma in the subglottic area. His chief symptoms were hoarseness and mild ... Chondrosarcoma is categorized as a malignant cartilaginous tumor, which occurs rarely in the craniofacial region. ... Chondrosarcoma of the head and neckLaryngoscopeYear: 199010013011305. 3. Jackson RS,Leon ME,McCaffrey TV. Chondrosarcoma of the ... Compared to chondrosarcomas in other systems, only 2-10% of all chondrosarcomas arise in the head and neck, with the majority ...
... Lohmander, Stefan LU ; Shinomura, T.; ... Rat chondrosarcoma chondrocytes were labeled with [3H]serine or [3H]mannose as a precursor. Intracellular proteoglycan core ... Rat chondrosarcoma chondrocytes were labeled with [3H]serine or [3H]mannose as a precursor. Intracellular proteoglycan core ... article{52f6a2c0-7074-42f4-ae84-0c0dbf6711b3, abstract = {,p,Rat chondrosarcoma chondrocytes were labeled with [,sup,3,/sup,H] ...
CT scan and gross pathology of a chondrosarcoma 2012-12-18 "Chondrosarcoma : Cancerbackup". Archived from the original on 2008- ... Therapeutic molecular targets in human chondrosarcoma .Int J Exp Pathol 2010; 91:387-93 Media related to Chondrosarcoma at ... A chondrosarcoma is a member of a category of tumors of bone and soft tissue known as sarcomas. About 30% of bone sarcomas are ... Chondrosarcoma is a bone sarcoma, a primary cancer composed of cells derived from transformed cells that produce cartilage. ...
EEOICPA BULLETIN NO.02-16 Issue Date: July 15, 2002. ________________________________________________________________. Effective Date: June 12, 2002. ________________________________________________________________. Expiration Date: June 12, 2003. ________________________________________________________________. Subject: Ureter Cancer as a Specified Primary Cancer Background: The Department of Labor (DOL) recently forwarded the medical evidence in a case file to the National Cancer Institute (NCI) for their review and opinion to determine if, for purposes of being considered a specified cancer under the EEOICPA, ureter cancer can be considered urinary bladder cancer.. The expert medical opinion obtained from the NCI indicates that superficial transitional cell carcinomas of the urinary epithelium are biologically identical wherever they arise within the urinary tract and indeed, they are often multifocal. The etiologic (including environmental) influences on urothelial carcinogenesis and the ...
Contact the Orthopaedic Oncology Service at Mass General for more information about treatment for Chondrosarcoma. ... Chondrosarcoma is a malignant cartilaginous tumor. It occurs most often in adults between 40-60 years of age. This tumor ... Chondrosarcoma. Chondrosarcoma is a malignant cartilaginous tumor. It occurs most often in adults between 40-60 years of age. ... Clear cell chondrosarcoma and intermediate or middle grade chondrosarcomas are less likely to spread to other areas. ...
Katonis P et al (2011) Spinal chondrosarcoma: a review. Sarcoma 2011:378957, 10 pagesCrossRefPubMedPubMedCentralGoogle Scholar ... Strike SA, McCarthy EF (2011) Chondrosarcoma of the spine: a series of 16 cases and a review of the literature. Iowa Orthop J ... Špero M. (2018) Neurinoma: Chondrosarcoma of the Thoracic Spine. In: Neuroradiology - Expect the Unexpected. Springer, Cham. * ... Lloret I et al (2006) Primary spinal chondrosarcoma: radiologic findings with pathological correlation. Acta Radiol 47(1):77-84 ...
Chondrosarcoma is a collective term for a group of tumors that consist predominantly of cartilage and that range from low-grade ... encoded search term (Chondrosarcoma) and Chondrosarcoma What to Read Next on Medscape. Related Conditions and Diseases. * Fast ... Chondrosarcoma types and grades. Different types of chondrosarcoma have been described, as follows:. * Conventional ... Different types of chondrosarcoma have been described, as follows:. * Conventional chondrosarcoma, which accounts for nearly 90 ...
Symptoms of Chondrosarcoma in Dogs. Symptoms of chondrosarcoma vary and will depend on the location of the tumor in the dogs ... Spinal chondrosarcoma often shows no visible signs.. If chondrosarcoma has spread to the lungs, the dog may exhibit other ... Treatment of Chondrosarcoma in Dogs. Treatment of chondrosarcoma in dogs must be aggressive. Most dogs are not symptomatic ... Diagnosis of Chondrosarcoma in Dogs. A dog suspected of chondrosarcoma will receive a complete physical and orthopedic ...
... risk factors and treatment of chondrosarcoma, a rare tumor of the cartilage of the bone, from the experts at Cedars-Sinai. ...
Chondrosarcoma is a rare type of cancer that primarily affects bone, particularly in the pelvis, hips and base of the skull. ... See a list of publications about chondrosarcoma by Mayo Clinic doctors on PubMed, a service of the National Library of Medicine ... Expand knowledge about some of the most rare varieties of chondrosarcoma. *Improve the ability to tailor the treatment of less- ... Mayo Clinic doctors and researchers continue to study new ways to diagnose and treat chondrosarcomas. Research includes ...
Intramedullary Chondrosarcoma of Proximal Humerus, Pratiksha Yadav, Dolly Thakkar, and S. S. Thind Case Reports in Radiology ... P. Yadav, D. Thakkar, and S. S. Thind, "Intramedullary chondrosarcoma of proximal humerus," Case Reports in Radiology, vol. ... Retracted: Intramedullary Chondrosarcoma of Proximal Humerus. Case Reports in Radiology. Received 1 March 2016; Accepted 1 ... The article titled "Intramedullary Chondrosarcoma of Proximal Humerus" [1] has been retracted as it was found to contain a ...
Chondrosarcoma is a rare type of cancer that primarily affects bone, particularly in the pelvis, hips and base of the skull. ... Chondrosarcoma is associated with certain genetic mutations. Some varieties of chondrosarcoma arise from the transformation of ... The defining characteristic of a chondrosarcoma is that its cells produce cartilage. Some types of chondrosarcomas grow slowly ... Chondrosarcoma is a rare type of cancer that usually begins in the bones, but can sometimes occur in the soft tissue near bones ...
Synovial Chondrosarcoma Arising in Synovial Chondromatosis. Scott Evans, Michele Boffano, Samena Chaudhry, Lee Jeys, and Robert ... F. Bertoni, K. K. Unni, J. W. Beabout, and F. H. Sim, "Chondrosarcoma of the synovium," Cancer, vol. 67, pp. 155-162, 1991. ... L. D. Rybak, L. Khaldi, J. Wittig, and G. C. Steiner, "Primary synovial chondrosarcoma of the hip joint in a 45-year-old male: ... W. K. Taconis, R. O. van der Heul, and A. M. M. Taminiau, "Synovial chondrosarcoma: report of a case and review of the ...
Chondrosarcoma (grades I-III), including primary and secondary variants and periosteal chondrosarcoma. In: World Health ... Chordoma and chondrosarcoma of the skull base. Author. Carl Snyderman, MD, MBA. Carl Snyderman, MD, MBA ... Chordoma and chondrosarcoma arising in the skull base will be reviewed here. Topics discussed elsewhere include:. ●Chordomas ... Chondrosarcoma of the base of the skull: a clinicopathologic study of 200 cases with emphasis on its distinction from chordoma ...
... Summary Global Markets Directs latest Pharmaceutical and Healthcare disease pipeline ... www.reportlinker.com/p0923775/Chondrosarcoma-Pipeline-Review-H1.htmlChondrosarcoma ... NEW YORK, June 8, 2017 /PRNewswire/ -- Chondrosarcoma - Pipeline Review, H1 2017SummaryGlobal Markets Directs ... latest Pharmaceutical and Healthcare disease pipeline guide Chondrosarcoma - Pipeline Review, H1 2017, provides an overview of ...
However, chondrosarcoma forms in cartilage, the tough but flexible tissue that pads the… ... Chondrosarcoma is a type of cancer closely related to bone cancer. ... Chondrosarcoma. What Is It?. Published: August, 2014. Chondrosarcoma is a type of cancer closely related to bone cancer. ... However, chondrosarcoma forms in cartilage, the tough but flexible tissue that pads the ends of bones and lines joints, not in ...
A case of primary chondrosarcoma of the lung is described in a 64-year-old man. The tumour was removed by lobectomy and he ...
Proton Beam Therapy for Chondrosarcoma. The safety and scientific validity of this study is the responsibility of the study ... Chondrosarcoma. Neoplasms, Connective Tissue. Neoplasms, Connective and Soft Tissue. Neoplasms by Histologic Type. Neoplasms. ... Pathologically confirmed Grade 1-3 chondrosarcoma of the skull base. *Contrast enhanced postop MRI or CT if there is clinical ... Patients who have skull base chondrosarcoma require complicated treatment because of its challenging location and nearness to ...
Dedifferentiated chondrosarcoma The anteroposterior radiograph of the pelvis shows a lytic, expansile lesion of the right ... Dedifferentiated chondrosarcoma occurs in approximately 11% of patients diagnosed with chondrosarcoma and is considered to be a ... Dedifferentiated chondrosarcoma is an aggressive subtype of chondrosarcoma that is characterized by a cartilaginous component ... Dedifferentiated chondrosarcoma. By Charles E. Lohr, III, MD; Bahair H. Ghazi, MD; Mark H. Schwab, MD; William A. Krantz, Jr., ...
Nasal and Paranasal Sinus Chondrosarcoma in Cats. Nasal and paranasal sinus chondrosarcoma are slow growing, progressive, ... Chondrosarcoma (Nasal and Paranasal Sinus) in Cats. 12 Jul, 2015 Dr. Bari Spielman 12,512 Views ... Chondrosarcoma tends to develop at a younger age than other nasal tumors. There are no breed predilections. ... Overall, nasal and paranasal sinus chondrosarcomas are very aggressive and carry a guarded prognosis. ...
A chondrosarcoma (CSA) is a malignant, invasive and fast spreading tumor in cats. It is relatively uncommon in cats, ... Chondrosarcoma of the Nasal and Paranasal Sinuses in Cats. A chondrosarcoma (CSA) is a malignant, invasive and fast spreading ... Bone Cancer (Chondrosarcoma) in Cats. Chondrosarcoma (CSA) is a type of cancer that affects the cartilage of the body; the ... Throat Cancer (Chondrosarcoma) in Cats Chondrosarcoma (throat cancer) is more common in middle aged and older cats. All breeds ...
What is chondrosarcoma? The Liddy Shriver Sarcoma Initiative website. Available at: ...(Click grey area to select URL). Updated ... Chondrosarcoma is graded from 1-4. Grade 1 is a local cancer. Grade 4 shows it has spread to other sites in the body. ... Chondrosarcoma is more common in adults after aged 20-60 years old. Your chances are also higher for:. *Enchondroma-harmless ... Chondrosarcoma is treated with surgery. The tumor is removed with a border of healthy tissue around it. In some cases, ...
Purchase Chordomas and Chondrosarcomas of the Skull Base and Spine - 2nd Edition. Print Book & E-Book. ISBN 9780128042571, ... Chordomas and Chondrosarcomas of the Skull Base: Transpetrosal Approaches 18. Chordomas and Chondrosarcomas of the Skull Base: ... Heavy Ion Radiation for Chordomas and Chondrosarcomas. SECTION VI: SPECIAL CONSIDERATIONS. 36. Chordomas and Chondrosarcomas in ... 7. Imaging Cranial Base Chordoma and Chondrosarcoma. 8. Imaging Chordoma and Chondrosarcoma of the Vertebrae and Sacrum ...
I encourage you to do a search of the CSN website by entering the key word "chondrosarcoma" in the search bar at the top of the ... You have similar case with me.I have chondrosarcoma skull base. I had 5 surgeries now. I just wish I could read some ... I had a skull based chondrosarcoma surgically removed from behind my right ear in 1990. Another was diagnosed, growing in the ... I was diagnosed with Chondro sarcoma in September 2015. Another freind of mine was diagnosed with the same cancer around the ...
Part of the NBL Cell Line Collection. This cell line is neither produced nor fully characterized by ATCC. We do not guarantee that it will maintain a specific morphology, purity, or any other property upon passage.
Chondrosarcomas are in general resistant to chemotherapy and radiotherapy. This review discusses recent developments in the ... characterization of molecular pathways involved in the oncogenesis of chondrosarcoma that should be explored to improve ... The prognosis of patients with unresectable or metastatic chondrosarcoma of the bone is poor. ... As chondrosarcoma is an orphan disease consequently all studies are performed with small numbers of patients. The results of ...
Chondrosarcoma in the young. A clinicopathologic analysis of 79 patients younger than 21 years of age. Am J Surg Pathol 1987;11 ... Mesenchymal chondrosarcoma of the jaws. Oral Surg Oral Md Oral Pathol 1982;54:197-206. [ Links ]. ... Mesenchymal chondrosarcoma of bone and soft tissue. A review of 111 cases. Cancer 1986;57:2444-453. [ Links ]. ... Aryoshi Y, Shimahara M. Mesenchymal chondrosarcoma of the maxilla: report of a case. J Oral Maxillofac Surg 1999;57:733-7. [ ...
  • A chondrosarcoma is one of several types of laryngeal tumors that can effect the larynx and trachea of a dog. (petmd.com)
  • Surgery is the main treatment for most types of chondrosarcoma. (cancer.ca)
  • Mesenchymal chondrosarcoma is an aggressive, high-grade type of chondrosarcoma. (cancer.ca)
  • A dedifferentiated chondrosarcoma tumour is treated like an osteosarcoma tumour because it is a more aggressive type of chondrosarcoma. (cancer.ca)
  • Dedifferentiated chondrosarcoma may be treated with some of the same chemotherapy drugs that are used for osteosarcoma . (cancer.ca)
  • The NR4A3 nuclear receptor is implicated in the development of extraskeletal myxoid chondrosarcoma (EMC), primitive sarcoma unrelated to conventional chondrosarcomas, through a specific fusion with EWSR1 resulting in an aberrant fusion protein that is thought to disrupt the transcriptional regulation of specific target genes. (nih.gov)
  • The cancer is different from the other sarcoma due to the presence of the unique myxoid chondrosarcoma. (healthadvicer.com)
  • Clear-cell chondrosarcoma is a variant of chondrosarcoma which is characterized by a typical histomorphology and a very slow rate of growth. (uu.nl)
  • Histology of the distal femur lesion excised at the time of endoprosthetic replacement confirmed this to be a primary chondrosarcoma. (bmj.com)
  • Histology from the excised distal femur did not show metastatic breast carcinoma as expected, but identified a primary chondrosarcoma ( figure 3 ). (bmj.com)
  • Histology from the previous breast and lung biopsies were reviewed in multiple centres to exclude the possibility of misdiagnosed dedifferentiated chondrosarcoma spreading to breast and lung, and eventually two separate primary cancers were confirmed. (bmj.com)
  • Histology of chondrosarcoma femur. (bmj.com)
  • Chondrosarcoma is the second most common type of primary bone cancer. (hopkinsmedicine.org)
  • Chondrosarcoma is a type of cancer. (coliseumhealthsystem.com)
  • If your doctor suggests you have chondrosarcoma, then it means you have bone cancer. (healthadvicer.com)
  • Chondrosarcoma is the rare type of bone cancer. (healthadvicer.com)
  • Chondrosarcoma, according to statistical estimates, approximately 10% of known cases of bone cancer. (doclandmed.com)
  • Among upregulated targets were the cluster of cancer testis antigens ( CTA ) genes, located on chromosome X. Their expression correlated to IGFR pathway activity, suggesting that massive (more than 100-fold) upregulation of CTA genes in chondrosarcoma is due to hypomethylation under control of epi-miRNAs, a specific group of miRNAs that affect the expression of tumor suppressor genes. (healthcanal.com)
  • Differential diagnosis against extraskeletal myxoid chondrosarcoma (EMC) may be problematic, particularly in an incisional biopsy. (kuleuven.be)
  • Peripheral chondrosarcoma (PCS) remains a malignancy for which no treatments other than radical surgery have proven effective. (curesarcoma.org)
  • Chondrosarcomas are the second most common bone malignancy and do not respond to conventional therapy. (healthcanal.com)
  • The EWSR1/NR4A3 fusion protein of extraskeletal myxoid chondrosarcoma activates the PPARG nuclear receptor gene. (nih.gov)
  • It is also known as EMC (Extraskeletal Myxoid Chondrosarcoma). (healthadvicer.com)
  • An extraskeletal chondrosarcoma of the maxilla. (uthscsa.edu)
  • This study was aimed to identify the roles of miR-129-5p-5p in regulation of SOX4 and Wnt/β-catenin signaling pathway, as well as cell proliferation and apoptosis in chondrosarcomas. (figshare.com)
  • MiR-129-5p inhibits the Wnt/β-catenin signaling pathway by targeting SOX4 and further suppresses cell proliferation, migration and promotes apoptosis in chondrosarcomas. (figshare.com)
  • Rat chondrosarcoma chondrocytes were labeled with [ 3 H]serine or [ 3 H]mannose as a precursor. (lu.se)
  • Together with H. Thomas Temple, M.D., professor and Vice Chair of Orthopedics and Director of the Tissue Bank, who in 2010 established the Musculoskeletal Oncology Signal Transduction Laboratory to investigate the molecular pathways leading to metastatic sarcomas, Galoian and her team compared and analyzed differentially expressed miRNA and their targets in chondrosarcoma versus control chondrocytes. (healthcanal.com)
  • We established an in vitro system for studying the effect of Se in the chondrosarcoma cell line SW-1353 and in human primary chondrocytes. (duke.edu)
  • As with many sarcomas, chondrosarcoma of the larynx and trachea is more common in middle aged and older dogs. (petmd.com)
  • Being aggressive and malignant in nature, chondrosarcomas of the larynx and trachea are usually life-threatening. (petmd.com)
  • Radiotherapy is generally not effective in patients with chondrosarcoma of the larynx and trachea. (petmd.com)
  • We present a case of pathological fracture of a distal femur in a patient with known metastatic breast carcinoma, which turned out to be another primary tumour, a chondrosarcoma. (bmj.com)
  • Limb-sparing surgery may be used to treat chondrosarcoma in the arm, leg and pelvis. (cancer.ca)
  • External beam radiation therapy may be used to treat chondrosarcoma that can't be removed with surgery. (cancer.ca)
  • Radiation therapy is also used for recurrent chondrosarcoma. (cancer.ca)
  • Nasal chondrosarcoma involving the entire left nasal cavity with breach of the central region of the nasal septum and tumor extension into the right nasal cavity. (merckvetmanual.com)
  • One possible explanation is that chondrosarcoma cells have lost their sense of direction. (curesarcoma.org)
  • However, the effects of COX-2 on migration activity in human chondrosarcoma cells are mostly unknown. (biomedcentral.com)
  • We found that over-expression of COX-2 or exogenous PGE 2 increased the migration of human chondrosarcoma cells. (biomedcentral.com)
  • Our results indicated that PGE 2 enhances the migration of chondrosarcoma cells by increasing α2β1 integrin expression through the EP1/PLC/PKCα/c-Src/NF-κB signal transduction pathway. (biomedcentral.com)
  • The expression of miR-129-5p was significantly down-regulated in chondrosarcoma tissues as well as cells in comparison with normal ones, while SOX4 was over-activated. (figshare.com)
  • In this study, we examined whether COX-2 and EP interaction are involved in metastasis of human chondrosarcoma. (biomedcentral.com)
  • Primary chondrosarcoma of the breast, although very rare, has been reported previously. (bmj.com)
  • Clinically, surgical resection remains the primary mode of therapy for chondrosarcoma. (biomedcentral.com)
  • It is used to treat a chondrosarcoma in the bones of the skull or spine, as well as in the arm, leg and pelvis. (cancer.ca)
  • The findings suggest a pedunculated chondroid lesion arising from the internal aspect of the right sphenoid wing, most likely chondrosarcoma. (radiopaedia.org)
  • A case of chondrosarcoma of the mandible of surgical failure was treated by radiation, hyperthermia, and bleomycin. (elsevier.com)
  • Unfortunately, final pathology from the surgical specimen revealed a chondrosarcoma. (regionh.dk)
  • Chemotherapy is not used for low-grade chondrosarcoma because it has not been shown to help improve survival. (cancer.ca)
  • The use of chemotherapy may depend on the type of chondrosarcoma that you have. (coliseumhealthsystem.com)
  • Chemotherapy in the chondrosarcoma is not used, the radiation therapy gives only a minor effect. (doclandmed.com)
  • It may be used after curettage to treat some small, low-grade chondrosarcoma tumours. (cancer.ca)
  • We now report the first mouse genetic model of peripheral chondrosarcoma, which is completely penetrant. (curesarcoma.org)
  • Chondrosarcomas have been observed as a late consequence of radiation therapy for other cancers. (hopkinsmedicine.org)
  • These results indicate, in agreement with our previous kinetic data, that the major part of the xylosyl transfer to the chondrosarcoma proteoglycan core protein precursor must occur late in the processing sequence, i.e. after about 85% of its intracellular lifetime and no more than 7 min before the addition of the rest of the chondroitin sulfate chain. (lu.se)
  • Since chondrosarcoma is a type of highly malignant tumor with a potent capacity to invade locally and metastasize distantly [ 2 ], an approach that decreases its ability to invade and metastasize may facilitate the development of effective adjuvant therapy. (biomedcentral.com)